Control of primary IgM antibody responses to H-2 alloantigens by antigen-bearing live B lymphocytes

1982 ◽  
Vol 12 (9) ◽  
pp. 713-719 ◽  
Author(s):  
Izumi Nakashima ◽  
Kenji Mizoguchi ◽  
Nobuo Kato ◽  
Fumihiko Nagase ◽  
Ken-Ichi Isobe ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Antibody Responses ◽  
Igm Antibody

scholarly journals IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jyotsna Shah ◽  
Song Liu ◽  
Hari-Hara Potula ◽  
Prerna Bhargava ◽  
Iris Cruz ◽  
...  
Keyword(s):  
Viral Infections ◽  
Antibody Responses ◽  
Nucleocapsid Proteins ◽  
Igm Antibodies ◽  
Igm Antibody ◽  
Specificity And Sensitivity ◽  
The Us ◽  
Autoimmune Conditions ◽  
Antibody Positivity ◽  
Recombinant Nucleocapsid Protein

Abstract Background Rapid and simple serological assays for characterizing antibody responses are important in the current COVID-19 pandemic caused by SARS-CoV-2. Multiplex immunoblot (IB) assays termed COVID-19 IB assays were developed for detecting IgG and IgM antibodies to SARS-CoV-2 virus proteins in COVID-19 patients. Methods Recombinant nucleocapsid protein and the S1, S2 and receptor binding domain (RBD) of the spike protein of SARS-CoV-2 were used as target antigens in the COVID-19 IBs. Specificity of the IB assay was established with 231 sera from persons with allergy, unrelated viral infections, autoimmune conditions and suspected tick-borne diseases, and 32 goat antisera to human influenza proteins. IgG and IgM COVID-19 IBs assays were performed on 84 sera obtained at different times after a positive RT-qPCR test from 37 COVID-19 patients with mild symptoms. Results Criteria for determining overall IgG and IgM antibody positivity using the four SARS-CoV-2 proteins were developed by optimizing specificity and sensitivity in the COVID-19 IgG and IgM IB assays. The estimated sensitivities and specificities of the COVID-19 IgG and IgM IBs for IgG and IgM antibodies individually or for either IgG or IgM antibodies meet the US recommendations for laboratory serological diagnostic tests. The proportion of IgM-positive sera from the COVID-19 patients following an RT-qPCR positive test was maximal at 83% before 10 days and decreased to 0% after 100 days, while the proportions of IgG-positive sera tended to plateau between days 11 and 65 at 78–100% and fall to 44% after 100 days. Detection of either IgG or IgM antibodies was better than IgG or IgM alone for assessing seroconversion in COVID-19. Both IgG and IgM antibodies detected RBD less frequently than S1, S2 and N proteins. Conclusions The multiplex COVID-19 IB assays offer many advantages for simultaneously evaluating antibody responses to different SARS-CoV-2 proteins in COVID-19 patients.

scholarly journals Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

2021 ◽  
pp. 113046
Author(s):  
A.M. Cook ◽  
S.E. Faustini ◽  
L.J. Williams ◽  
A.F. Cunningham ◽  
M.T. Drayson ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Igm Antibody ◽  
Hospitalised Patients

scholarly journals Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

2020 ◽  
Vol 9 (1) ◽  
pp. 1096-1101 ◽  
Author(s):  
Liang Shen ◽  
Chunhua Wang ◽  
Jianzhong Zhao ◽  
Xiaoyong Tang ◽  
Ying Shen ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Igm Antibody

Gene family use and somatic mutation in primary and secondary fluorescein-specific IgM antibody responses

1996 ◽  
Vol 74 (3) ◽  
pp. 245-254 ◽  
Author(s):  
H VAN DER KEYL ◽  
C HSU ◽  
A TOLAT ◽  
S KANSIL ◽  
MR DALESANDRO ◽  
...  
Keyword(s):  
Gene Family ◽  
Somatic Mutation ◽  
Antibody Responses ◽  
Igm Antibody

scholarly journals Role of a nonimmunoglobulin cell surface determinant in the activation of B lymphocytes by thymus-independent antigens.

1979 ◽  
Vol 149 (2) ◽  
pp. 495-506 ◽  
Author(s):  
B Subbarao ◽  
D E Mosier ◽  
A Ahmed ◽  
J J Mond ◽  
I Scher ◽  
...  
Keyword(s):  
Cell Surface ◽  
B Cell ◽  
B Lymphocytes ◽  
Selective Inhibition ◽  
Antibody Responses ◽  
Antigenic Determinants ◽  
Functional Assay ◽  
Induce Antibody

Lyb 5 is a B-cell alloantigen which is expressed on 50-60% of B cells. It was defined originally on the basis of cytotoxicity. We have described a new reactivity within the anti-Lyb 5 serum on the basis of selective inhibition of antibody responses in vitro by this antiserum in the absence of complement. This inhibitory activity of anti-Lyb 5.1 serum appears to be due to recognition of antigenic determinants different from the prototype antigens detected in the cytotoxicity assay. Anti-Lyb 5 serum incorporated into spleen cell cultures selectively inhibits antibody responses to a class of thymus-independent antigens (TI-2) previously characterized by their failure to elicit antibody formation in immature mice or in the defective CBA/N strain. Responses to optimal concentrations of TI-1 antigens, which can induce antibody synthesis in these mice, are unaffected by the addition of anti-Lyb 5.1 serum. The B-cell alloantigen defined by this functional assay is designated tentatively Lyb 7 and it is shown to be distinct from cell surface immunoglobulins. Lyb 7 appears to have a role in the activation of B lymphocytes by the TI-2 class of thymus-independent antigens.

Sign in / Sign up

Export Citation Format

Share Document